Risk evaluation of early-stage hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients: a population-based study from Taiwan

doi:10.1007/s10549-021-06330-4

HFCAS OpenIR

	Risk evaluation of early-stage hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients: a population-based study from Taiwan
	Lei, Lei 1; Chan, Han-Ching 2; Lu, Tzu-Pin 2; Cheng, Skye Hung-Chun 3,4
	2021-07-19
发表期刊	BREAST CANCER RESEARCH AND TREATMENT
ISSN	0167-6806
通讯作者	Cheng, Skye Hung-Chun(skyecheng@gmail.com)
摘要	Purpose To assess the prognostic value of the Dutch criteria for patients with early-stage hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer from the Taiwan Cancer Registry Database. Patients and methods We included 8295 patients with early-stage node-negative breast cancer who underwent surgery during January 2008-December 2012. Patients were stratified into low- and high-risk groups based on the Dutch criteria. The Kaplan-Meier method and log-rank test were used to estimate the difference in breast cancer-specific survival (BCSS) and overall survival (OS) between groups. Multivariable analysis was used to evaluate the prognostic value of the Dutch criteria. Results Overall, the low-risk and high-risk groups comprised 5375 and 2920 patients, respectively. In the low- and high-risk groups, the 5-year BCSS rate was 99.6% and 98.2% (P < 0.0001) and the 5-year OS rate was 98.3% and 96.8% (P < 0.0001), respectively. The hazard ratio for BCSS was 4.18 (95% confidence interval [CI] 2.63-6.63, P < 0.0001), and the hazard ratio for OS was 1.94 (95% CI 1.48-2.55); both were significantly poorer in the high-risk group than in the low-risk group. In the low-risk group, the 5-year BCSS and OS of patients who did and did not receive adjuvant chemotherapy were similar (99.5% versus 99.6% [P = 0.927] and 98.8% and 98.1% [P = 0.0683], respectively). Conclusion The prognosis of low-risk patients as classified using the Dutch criteria is excellent with or without adjuvant chemotherapy. The benefit of multi-gene testing for chemotherapy decision-making might be minimal in these patients.
关键词	Human epidermal growth factor receptor 2 Breast cancer Dutch criteria Taiwan
DOI	10.1007/s10549-021-06330-4
关键词[WOS]	RECURRENCE SCORE ASSAY ; CHEMOTHERAPY ; SURVIVAL ; IMPACT
收录类别	SCI
语种	英语
资助项目	Ministry of Science and Technology, Taipei, Taiwan[MOST 105-2314-B-368-001] ; Hammer Family Fund (2018-2020) ; Zhejiang Public Welfare Technology Research Program[LGJ20H160001]
项目资助者	Ministry of Science and Technology, Taipei, Taiwan ; Hammer Family Fund (2018-2020) ; Zhejiang Public Welfare Technology Research Program
WOS研究方向	Oncology
WOS类目	Oncology
WOS记录号	WOS:000674549800002
出版者	SPRINGER
引用统计
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/123309
专题	中国科学院合肥物质科学研究院
通讯作者	Cheng, Skye Hung-Chun
作者单位	1.Univ Chinese Acad Sci, Breast Oncol Dept, Canc Hosp, Beijing, Zhejiang, Peoples R China 2.Natl Taiwan Univ, Inst Epidemiol & Prevent Med, Dept Publ Hlth, Taipei, Taiwan 3.Sun Yat Sen Canc Ctr, Dept Radiat Oncol, Koo Fdn, Taipei, Taiwan 4.Taitung Christian Hosp, Taitung Canc Ctr, Taitung, Taiwan
推荐引用方式 GB/T 7714	Lei, Lei,Chan, Han-Ching,Lu, Tzu-Pin,et al. Risk evaluation of early-stage hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients: a population-based study from Taiwan[J]. BREAST CANCER RESEARCH AND TREATMENT,2021.
APA	Lei, Lei,Chan, Han-Ching,Lu, Tzu-Pin,&Cheng, Skye Hung-Chun.(2021).Risk evaluation of early-stage hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients: a population-based study from Taiwan.BREAST CANCER RESEARCH AND TREATMENT.
MLA	Lei, Lei,et al."Risk evaluation of early-stage hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients: a population-based study from Taiwan".BREAST CANCER RESEARCH AND TREATMENT (2021).